New hope for transplant patients: immune cell therapy targets stubborn graft-versus-host disease
Disease control
Recruiting now
This early-phase study tests whether a single dose of specially grown regulatory T cells, combined with daily low-dose interleukin-2, can safely treat chronic graft-versus-host disease (cGvHD) in people whose condition did not improve with steroids or IL-2 alone. About 21 partici…
Phase: PHASE1 • Sponsor: Leslie Kean • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC